BioSpace News Archive

Johnson & Johnson announced updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with carcinoma in situ, who are ineligible for, or decline, radical cystectomy.

Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).

UroGen Pharma Ltd. today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market.

Inozyme Pharma, Inc. today announced that it granted stock options to one new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to the new employees.

Form Bio, the breakthrough computational life sciences solutions provider, today announced that it will deliver multiple presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an abstract in amyotrophic lateral sclerosis (ALS) at the Professional Society for Health Economics and Outcomes Research (ISPOR) 2024 Annual Meeting, being held in Atlanta, Ga., May 5-8, 2024.

Illumina, Inc. announced that its executives will be speaking at the following investor conference.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board of directors, subject to approval of the Canadian Securities Exchange.

BioSig Technologies, Inc. or, a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, announced new appointments to its now fully constituted board of directors, which is comprised of a total of five directors, three of whom are classified as independent directors.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees.